Rosaura Casas
Linkoeping, E 58183, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial.
Journal: International journal of molecular sciences
Published: November 25, 2024
A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes.
Journal: Diabetes, obesity & metabolism
Published: April 23, 2023
Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
Journal: Frontiers in immunology
Published: November 30, 2022
Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol.
Journal: BMJ open
Published: October 31, 2022
Regulatory T-Cell Phenotyping Using CyTOF.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: September 30, 2022
Pregnancy induces pancreatic insulin secretion in women with long-standing type 1 diabetes.
Journal: BMJ open diabetes research & care
Published: May 17, 2022
Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.
Journal: The Journal of clinical endocrinology and metabolism
Published: February 25, 2022
Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial).
Journal: Acta diabetologica
Published: October 23, 2021
Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes.
Journal: Frontiers in immunology
Published: October 18, 2021
Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes.
Journal: Immunotherapy advances
Published: September 13, 2021
Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes.
Journal: Diabetes/metabolism research and reviews
Published: March 19, 2021
Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial.
Journal: Diabetes care
Published: February 06, 2021
Last Updated: 09/26/2026